Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
NCT04433182 · Fondazione Italiana Linfomi - ETS · PHASE2 · terminated · last registry update 2025-08-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low enrollment rate” | – | Registry record, Fondazione Italiana Linfomi - ETS |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-07Results posted on the registry: M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-07-07Also stopped (terminated): M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-06-25Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT05631795)
- 2026-06-04Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Olaparib (NCT04729387)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Rituximab + Copanlisib (NCT03789240)
- 2026-02-13Also stopped (suspended): Dana-Farber Cancer Institute, Palbociclib + Gedatolisib (NCT03065062)
- 2026-02-09Also stopped (withdrawn): Hoffmann-La Roche, Inavolisib + Bevacizumab (NCT07323576)
- 2026-02-04Also stopped (terminated): Centre Hospitalier Universitaire Dijon, Taselisib (GDC0032) + Taselisib (GDC0032) (NCT03290092)
- 2026-01-22Results posted on the registry: Jennifer Lee Caswell-Jin, Alpelisib + Tamoxifen (NCT05101564)
- 2026-01-09Also stopped (terminated): M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
- 2025-09-08Also stopped (terminated): Institut Curie, PF-05212384 (NCT02438761)
- 2025-08-03Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Durvalumab (NCT03842228)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
- 2025-07-11Results posted on the registry: M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2025-06-15Also stopped (withdrawn): VA Office of Research and Development, copanlisib + Avelumab (NCT05687721)
- 2025-05-31Results posted on the registry: Bryan Schneider, MD, Capecitabine + Talazoparib (NCT04849364)
- 2025-05-31Also stopped (terminated): Bryan Schneider, MD, Capecitabine + Talazoparib (NCT04849364)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision